Setting

North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

Published: 28 Nov 2020 | Report Code: 10247773 | Pages: 111

North America preventive vaccines market is expected to grow by 9.98% annually in the forecast period and reach $30.01 billion by 2026 driven by increasing healthcare expenditure, advancing vaccine technology, and rising need for preventive vaccines especially new COVID-19 vaccines. Highlighted with 26 tables and 48 figures, this 111-page report “North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country. Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Live/Attenuated Vaccines • Inactivated Vaccines • Subunit Vaccines • Toxoid Vaccines • Conjugate Vaccines • Recombinant Vector Vaccines • Other Vaccines Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Vaccines for Pneumococcal Disease • Vaccines for Poliovirus • Vaccines for Hepatitis • Vaccines for Influenza • Vaccines for Measles, Mumps, and Rubella (MMR) • Vaccines for Varicella • Vaccines for Human Papilloma Virus • Vaccines for COVID-19 • Vaccines for Other Diseases Based on Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Intramuscular Route • Subcutaneous Route • Oral Route • Intravenous Injection • Other Administration Routes Based on Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. Pediatric Vaccines • Pneumococcal • Measles, Mumps, and Rubella (MMR) • Varicella • Hepatitis • Poliovirus • Haemophilus Influenzae B (HIB) • Other Diseases Adult Vaccines • Influenza • Cervical Cancer • Hepatitis • Zoster • Other Diseases Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline PLC Johnson & Johnson Merck & Co. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	6
1.1 Industry Definition and Research Scope	6
1.1.1 Industry Definition	6
1.1.2 Research Scope	7
1.2 Research Methodology	10
1.2.1 Overview of Market Research Methodology	10
1.2.2 Market Assumption	11
1.2.3 Secondary Data	11
1.2.4 Primary Data	11
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of North America Market by Vaccine Type	40
3.1 Market Overview by Vaccine Type	40
3.2 Live/Attenuated Vaccines	42
3.3 Inactivated Vaccines	43
3.4 Subunit Vaccines	44
3.5 Toxoid Vaccines	45
3.6 Conjugate Vaccines	46
3.7 Recombinant Vector Vaccines	47
3.8 Other Vaccines	48
4 Segmentation of North America Market by Disease	49
4.1 Market Overview by Disease	49
4.2 Vaccines for Pneumococcal Disease	51
4.3 Vaccines for Poliovirus	52
4.4 Vaccines for Hepatitis	53
4.5 Vaccines for Influenza	54
4.6 Vaccines for Measles, Mumps, and Rubella (MMR)	55
4.7 Vaccines for Varicella	56
4.8 Vaccines for Human Papilloma Virus	57
4.9 Vaccines for COVID-19	58
4.10 Vaccines for Other Diseases	59
5 Segmentation of North America Market by Administration	60
5.1 Market Overview by Administration	60
5.2 Intramuscular Route	62
5.3 Subcutaneous Route	63
5.4 Oral Route	64
5.5 Intravenous Injection	65
5.6 Other Administration Routes	66
6 Segmentation of North America Market by Patient	67
6.1 Market Overview by Patient	67
6.2 Pediatric Vaccines	69
6.3 Adult Vaccines	71
7 North America Market 2019-2026 by Country	73
7.1 Overview of North America Market	73
7.2 U.S.	76
7.3 Canada	81
7.4 Mexico	84
8 Competitive Landscape	87
8.1 Overview of Key Vendors	87
8.2 New Product Launch, Partnership, Investment, and M&A	90
8.3 Company Profiles	91
AstraZeneca plc	91
Bavarian Nordic A/S	93
China National Biotec Group Company Ltd.	94
CSL Ltd.	95
Daiichi Sankyo Co. Ltd	96
Emergent BioSolutions Inc.	97
GlaxoSmithKline PLC	98
Johnson & Johnson	99
Merck & Co.	100
Novavax, Inc.	101
Pfizer Inc.	102
Sanofi SA	103
Takeda Pharmaceutical Co. Ltd	104
9 Investing in North America Market: Risk Assessment and Management	105
9.1 Risk Evaluation of North America Market	105
9.2 Critical Success Factors (CSFs)	108
Related Reports and Products	111
?
List Of Tables

Table 1.  Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2019-2026	17
Table 2. Growth Rate of World Real GDP, 2017-2021	22
Table 3.  Main Product Trends and Market Opportunities in North America Preventive Vaccines Market	32
Table 4. North America Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	40
Table 5. North America Preventive Vaccines Market by Disease, 2016-2026, $ mn	49
Table 6. North America Preventive Vaccines Market by Administration, 2016-2026, $ mn	60
Table 7. North America Preventive Vaccines Market by Patient, 2016-2026, $ mn	67
Table 8. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn	70
Table 9. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn	72
Table 10. North America Preventive Vaccines Market by Country, 2016-2026, $ mn	74
Table 11. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	78
Table 12. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn	78
Table 13. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn	79
Table 14. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	82
Table 15. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn	82
Table 16. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn	83
Table 17. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	85
Table 18. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn	85
Table 19. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn	86
Table 20. AstraZeneca plc: Company Snapshot	91
Table 21. AstraZeneca plc: Business Segmentation	91
Table 22. AstraZeneca plc: Product Portfolio	92
Table 23. AstraZeneca plc: Revenue, 2016-2018, $ mn	92
Table 24. AstraZeneca plc: Recent Developments	92
Table 25.  Risk Evaluation for Investing in North America Market, 2019-2026	106
Table 26. Critical Success Factors and Key Takeaways	109

List Of Figures

Figure 1. Research Method Flow Chart	10
Figure 2. Breakdown of Primary Research	12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026	16
Figure 5. North America Preventive Vaccines Market, 2019-2026, $ mn	19
Figure 6. Development Stages of Preventive Vaccines	20
Figure 7. Impact of COVID-19 on Business	24
Figure 8. Primary Drivers and Impact Factors of North America Preventive Vaccines Market	26
Figure 9. Primary Restraints and Impact Factors of North America Preventive Vaccines Market	29
Figure 10. Investment Opportunity Analysis	33
Figure 11. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market	36
Figure 12. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue	41
Figure 13. Contribution to North America 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%)	41
Figure 14. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn	42
Figure 15. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn	43
Figure 16. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn	44
Figure 17. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn	45
Figure 18. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn	46
Figure 19. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn	47
Figure 20. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn	48
Figure 21. Breakdown of North America Preventive Vaccines Market by Disease, 2019-2026, % of Revenue	50
Figure 22. Contribution to North America 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%)	50
Figure 23. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn	51
Figure 24. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn	52
Figure 25. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn	53
Figure 26. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn	54
Figure 27. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn	55
Figure 28. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn	56
Figure 29. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn	57
Figure 30. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn	58
Figure 31. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn	59
Figure 32. Breakdown of North America Preventive Vaccines Market by Administration, 2019-2026, % of Revenue	61
Figure 33. Contribution to North America 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%)	61
Figure 34. North America Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn	62
Figure 35. North America Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn	63
Figure 36. North America Preventive Vaccines Market: Oral Route, 2016-2026, $ mn	64
Figure 37. North America Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn	65
Figure 38. North America Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn	66
Figure 39. Breakdown of North America Preventive Vaccines Market by Patient, 2019-2026, % of Revenue	67
Figure 40. Contribution to North America 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%)	68
Figure 41. North America Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn	69
Figure 42. North America Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn	71
Figure 43. Breakdown of North America Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue	74
Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)	75
Figure 45. U.S. Preventive Vaccines Market, 2016-2026, $ mn	77
Figure 46. Canada Preventive Vaccines Market, 2016-2026, $ mn	81
Figure 47.  Preventive Vaccines Market in Mexico, 2016-2026, $ mn	84
Figure 48. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period	87

Key Players (this may not be a complete list and extra companies can be added upon request): 
AstraZeneca plc	
Bavarian Nordic A/S	
China National Biotec Group Company Ltd.	
CSL Ltd.	
Daiichi Sankyo Co. Ltd	
Emergent BioSolutions Inc.	
GlaxoSmithKline PLC	
Johnson & Johnson	
Merck & Co.	
Novavax, Inc.	
Pfizer Inc.	
Sanofi SA	
Takeda Pharmaceutical Co. Ltd